seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitisseven-signal蛋白质组签名检测操作从自身免疫性胰腺炎胰腺导管腺癌和歧视.pdfVIP

Hindawi Publishing Corporation International Journal of Proteomics Volume 2012, Article ID 510397, 11 pages doi:10.1155/2012/510397 Research Article Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis Kiyoshi Yanagisawa,1, 2 Shuta Tomida,2 Keitaro Matsuo,3 Chinatsu Arima,2 Miyoko Kusumegi,4 Yukihiro Yokoyama,5 Shigeru B. H. Ko,6 Nobumasa Mizuno,7 Takeo Kawahara,5 Yoko Kuroyanagi,4 Toshiyuki Takeuchi,4 Hidemi Goto,6 Kenji Yamao,7 Masato Nagino,5 Kazuo Tajima,3 and Takashi Takahashi2 1 Institute for Advanced Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan 2 Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan 3 Division of Epidemiology and Prevention, Aichi Cancer Center, Nagoya 464-8681, Japan 4 Division of Research and Development, Oncomics Co., Ltd., Nagoya 464-0858, Japan 5 Division of Surgical Oncology, Department of Surgery, Nagoya University Hospital, Nagoya 466-8550, Japan 6 Department of Gastroenterology, Nagoya University Hospital, Nagoya 466-8550, Japan 7 Department of Gastroenterology, Aichi Cancer Center, Nagoya 464-8681, Japan Correspondence should be addressed to Kiyoshi Yanagisawa, kyana@med.nagoya-u.ac.jp Received 27 January 2012; Accepted 9 March 2012 Academic Editor: Visith Thongboonkerd Copyright © 2012 Kiyoshi Yanagisawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. There is urgent need for biomarkers that provide